Indeed, many of the heterogeneous oncogenic alterations that drive GBM including mutations, deletions, or amplifications in PTEN, EGFR, and PIK3CA can cause the similar metabolic phenotype of elevated de novo purine synthesis18–20,51. This evidence concerns the gene EGFR and glioblastoma.